Syngene International Limited Asset Resilience Ratio
Syngene International Limited asset resilience ratio. Syngene International Limited (SYNGENE) has an Asset Resilience Ratio of 16.68% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Syngene International Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Syngene International Limited (2010–2025)
Asset resilience ratio of Syngene International Limited from 2010 to 2025. This chart shows how Syngene International Limited's Asset Resilience Ratio has changed over time. Read SYNGENE liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Syngene International Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Syngene International Limited asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs3.27 Billion | 5.0% |
| Short-term Investments | Rs7.64 Billion | 11.68% |
| Total Liquid Assets | Rs10.91 Billion | 16.68% |
Asset Resilience Insights
- Good Liquidity Position: Syngene International Limited maintains a healthy 16.68% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Syngene International Limited Industry Peers by Asset Resilience Ratio
Compare Syngene International Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA |
Diagnostics & Research | 15.15% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Syngene International Limited Asset Resilience Ratio by Year (2010–2025)
Syngene International Limited asset resilience ratio by year from 2010 to 2025. The table below shows the annual Asset Resilience Ratio data for Syngene International Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 16.42% | Rs11.16 Billion ≈ $120.68 Million |
Rs67.96 Billion ≈ $734.95 Million |
+0.31pp |
| 2024-03-31 | 16.11% | Rs9.91 Billion ≈ $107.17 Million |
Rs61.52 Billion ≈ $665.27 Million |
-5.61pp |
| 2023-03-31 | 21.72% | Rs12.67 Billion ≈ $136.98 Million |
Rs58.31 Billion ≈ $630.60 Million |
+2.85pp |
| 2022-03-31 | 18.87% | Rs10.50 Billion ≈ $113.54 Million |
Rs55.64 Billion ≈ $601.70 Million |
+3.65pp |
| 2021-03-31 | 15.22% | Rs7.43 Billion ≈ $80.35 Million |
Rs48.83 Billion ≈ $528.10 Million |
-4.65pp |
| 2020-03-31 | 19.86% | Rs8.27 Billion ≈ $89.43 Million |
Rs41.63 Billion ≈ $450.20 Million |
-6.81pp |
| 2019-03-31 | 26.67% | Rs9.88 Billion ≈ $106.82 Million |
Rs37.03 Billion ≈ $400.52 Million |
-0.69pp |
| 2018-03-31 | 27.36% | Rs8.72 Billion ≈ $94.35 Million |
Rs31.89 Billion ≈ $344.88 Million |
-21.69pp |
| 2017-03-31 | 49.05% | Rs13.61 Billion ≈ $147.13 Million |
Rs27.74 Billion ≈ $299.98 Million |
+23.56pp |
| 2016-03-31 | 25.49% | Rs6.09 Billion ≈ $65.86 Million |
Rs23.89 Billion ≈ $258.42 Million |
+15.22pp |
| 2015-03-31 | 10.27% | Rs1.46 Billion ≈ $15.79 Million |
Rs14.21 Billion ≈ $153.73 Million |
-19.29pp |
| 2014-03-31 | 29.56% | Rs3.52 Billion ≈ $38.07 Million |
Rs11.91 Billion ≈ $128.79 Million |
+20.02pp |
| 2013-03-31 | 9.54% | Rs691.00 Million ≈ $7.47 Million |
Rs7.24 Billion ≈ $78.32 Million |
+9.03pp |
| 2011-03-31 | 0.52% | Rs26.00 Million ≈ $281.18K |
Rs5.04 Billion ≈ $54.52 Million |
-1.61pp |
| 2010-03-31 | 2.13% | Rs109.00 Million ≈ $1.18 Million |
Rs5.12 Billion ≈ $55.37 Million |
-- |
About Syngene International Limited
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and anal… Read more